Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (600671) — Cash Flow-to-Debt Ratio
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (600671) has a Cash Flow-to-Debt Ratio of -0.06x as of September 2025, meaning its operating cash flow of CN¥-19.96 Million could theoretically repay 0% of its total liabilities (CN¥335.43 Million) in one year. See Hangzhou TianMuShan Pharmaceutical Enter financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd Cash Flow-to-Debt Ratio (1998–2025)
Historical debt coverage capacity for Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd across 28 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Hangzhou TianMuShan Pharmaceutical Enter.
Annual Cash Flow-to-Debt Ratio for Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (1998–2025)
Year-by-year debt coverage analysis for Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd. Check Hangzhou TianMuShan Pharmaceutical Enter (600671) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.03x | CN¥11.79 Million | CN¥348.04 Million | ▲ +132.9% |
| 2024 | -0.10x | CN¥-36.67 Million | CN¥356.44 Million | ▼ -46.2% |
| 2023 | -0.07x | CN¥-20.43 Million | CN¥290.34 Million | ▼ -7.3% |
| 2022 | -0.07x | CN¥-19.37 Million | CN¥295.36 Million | ▲ +16.1% |
| 2021 | -0.08x | CN¥-26.42 Million | CN¥338.09 Million | ▼ -225.0% |
| 2020 | -0.02x | CN¥-8.40 Million | CN¥349.18 Million | ▼ -105.9% |
| 2019 | 0.41x | CN¥161.13 Million | CN¥393.60 Million | ▲ +131.0% |
| 2018 | 0.18x | CN¥70.71 Million | CN¥398.99 Million | ▲ +156.0% |
| 2017 | 0.07x | CN¥24.52 Million | CN¥354.18 Million | ▲ +934.1% |
| 2016 | 0.01x | CN¥1.61 Million | CN¥240.01 Million | ▲ +199.4% |
| 2015 | -0.01x | CN¥-1.47 Million | CN¥217.63 Million | ▼ -306.5% |
| 2014 | 0.00x | CN¥653.79K | CN¥200.40 Million | ▼ -93.9% |
| 2013 | 0.05x | CN¥12.37 Million | CN¥230.01 Million | ▲ +155.1% |
| 2012 | -0.10x | CN¥-19.82 Million | CN¥203.17 Million | ▼ -163.0% |
| 2011 | -0.04x | CN¥-6.49 Million | CN¥175.00 Million | ▲ +51.2% |
| 2010 | -0.08x | CN¥-12.60 Million | CN¥165.66 Million | ▼ -240.9% |
| 2009 | 0.05x | CN¥7.58 Million | CN¥140.53 Million | ▼ -67.2% |
| 2008 | 0.16x | CN¥21.19 Million | CN¥128.78 Million | ▼ -54.6% |
| 2007 | 0.36x | CN¥47.53 Million | CN¥131.16 Million | ▼ -24.1% |
| 2006 | 0.48x | CN¥55.39 Million | CN¥116.04 Million | ▲ +650.2% |
| 2005 | 0.06x | CN¥8.48 Million | CN¥133.32 Million | ▲ +395.6% |
| 2004 | 0.01x | CN¥1.35 Million | CN¥105.49 Million | ▲ +103.2% |
| 2003 | -0.40x | CN¥-41.13 Million | CN¥103.88 Million | ▼ -318.6% |
| 2002 | 0.18x | CN¥21.80 Million | CN¥120.32 Million | ▲ +170.6% |
| 2001 | 0.07x | CN¥10.52 Million | CN¥157.11 Million | ▲ +207.0% |
| 2000 | -0.06x | CN¥-9.67 Million | CN¥154.60 Million | ▼ -112.2% |
| 1999 | 0.51x | CN¥49.09 Million | CN¥95.68 Million | ▲ +1800.8% |
| 1998 | 0.03x | CN¥2.36 Million | CN¥87.30 Million | — |